Cargando…
Azithromycin: can its benefit be ruled out in mild COVID-19?
Autor principal: | Rodríguez-Molinero, Alejandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270520/ https://www.ncbi.nlm.nih.gov/pubmed/34252379 http://dx.doi.org/10.1016/S2213-2600(21)00289-7 |
Ejemplares similares
-
Azithromycin for severe COVID-19
por: Oldenburg, Catherine E, et al.
Publicado: (2020) -
Azithromycin, RECOVERY, and the power of large, simple trials
por: Berwanger, Otavio
Publicado: (2021) -
Covid-19 and the power of rules
por: Brady, Malcolm
Publicado: (2021) -
Azithromycin for mild-to-moderate COVID-19
por: Patel, Jigar, et al.
Publicado: (2021) -
Two years later, azithromycin for COVID-19 and the effect on the heart, is it still relevant?
por: Matoso Laranjo, Sérgio
Publicado: (2022)